Loi, Sherene <br/><br/>
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.  [electronic resource] 

 -  PloS one  2013 
 - e53292 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0053292  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--genetics<br/>Cell Proliferation<br/>Class I Phosphatidylinositol 3-Kinases<br/>Everolimus<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Genotype<br/>Humans<br/>Letrozole<br/>Middle Aged<br/>Mutation<br/>Nitriles--administration & dosage<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Receptors, Estrogen--metabolism<br/>Sirolimus--administration & dosage<br/>TOR Serine-Threonine Kinases--metabolism<br/>Triazoles--administration & dosage